Navigation Links
Pharmos Corporation Reports 2008 First Quarter Results
Date:5/8/2008

ISELIN, N.J., May 8 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the first quarter 2008 compared to a net loss of $4.8 million, or $0.19 per share, in the first quarter 2007. Cash and short-term investments totaled $11.3 million at March 31, 2008.

The decrease in net loss for the first quarter 2008 is due primarily to a 29% decrease in operating expenses, which was driven by a 68% decrease in general and administrative expenses to $0.8 million compared to $2.5 million in the first quarter 2007.

Research & development net, increased by $208,136 or 8%, from $2,570,098 in 2007 to $2,778,234 in 2008. Increased expenditures for the dextofisopam clinical trial are offset in part by the cost savings resulting from the downsizing and curtailment of general R&D programs. CB2 research and discovery and R&D overhead at our Rehovot facility were the areas of reduced spending.

During the first quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients, which is expected to enroll approximately 480 patients in about 70 sites over an 18 month period. Costs of $2.0 million were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc. which closed in October 2006. The continued development of this compound through late-stage clinical testing will significantly increase the research and development expenses going forward.

A Phase 2a clinical trial with t
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 17, 2011 Executives from NineSigma , Inc., the ... have written chapters on crucial elements of open innovation for ... Leading Experts. This bestselling book offers ... new solutions and capabilities outside of their organization and clearly ...
... and Ghent University have shown that a defective gene ... often-crippling inflammation of the joints that afflicts about 1% ... mechanism of the disease was largely unclear. In the ... demonstrate that a cell-specific defect in the expression of ...
... TARRYTOWN, N.Y., Aug. 16, 2011 Regeneron Pharmaceuticals, Inc. ... has received notification from the U.S. Food and Drug ... date to complete the priority review of the EYLEA ... age-related macular degeneration (wet AMD) to November 18, 2011, ...
Cached Biology Technology:From Leadership to Legal Issues, NineSigma Shares Best Practices in an Authoritative Guide to Open Innovation and CrowdSourcing 2Defect in A20 gene expression causes rheumatoid arthritis 2Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 2Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 3Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 4
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... , WASHINGTON, D.C., Dec. 15, 2011 Austen BioInnovation ... Drug Administration (FDA) have entered into a ground-breaking collaboration ... and effective use of biomaterials in medical devices. ... of Understanding that will allow the FDA to draw ...
... study has identified a gene mutation that researchers estimate dates ... disease mutation yet discovered. , Researchers with the Ohio State ... and Richard J. Solove Research Institute led the study and ... 13,600 years ago. Only a mutation seen in cystic fibrosis ...
... fetal exposure to carcinogens can vary substantially, a recent study ... depending on the stage of pregnancy when the fetus is ... in which toxic damage early in life can later manifest ... was done by scientists in the Linus Pauling Institute at ...
Cached Biology News:FDA, ABIA to collaborate on safety and performance of materials used in medical devices 2Scientists discover second-oldest gene mutation 2Cancer from fetal exposure to carcinogens depends on dose, timing 2
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: